Compare Stocks: REVB, EVLO, and EVFM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EVFM Evofem Biosciences	$0.01 +6.9%	$0.01	$0.00 ▼ $0.01	$822K	-1.41	197,422 shs	23,356 shs
EVLO Evelo Biosciences		$0.00	$0.00 ▼ $0.00	$2K	1.34	7,613 shs	25 shs
REVB Revelation Biosciences	$4.27 -2.5%	$5.21	$3.08 ▼ $40.60	$2.90M	-0.13	33,335 shs	2,490 shs

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EVFM Evofem Biosciences	-4.92%	-4.92%	-17.14%	-22.67%	-36.26%
EVLO Evelo Biosciences	0.00%	0.00%	-50.00%	0.00%	-80.00%
REVB Revelation Biosciences	+5.52%	+23.03%	-14.31%	-40.97%	-84.07%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EVFM Evofem Biosciences	$0.01 +6.9%	$0.01	$0.00 ▼ $0.01	$822K	-1.41	197,422 shs	23,356 shs
EVLO Evelo Biosciences		$0.00	$0.00 ▼ $0.00	$2K	1.34	7,613 shs	25 shs
REVB Revelation Biosciences	$4.27 -2.5%	$5.21	$3.08 ▼ $40.60	$2.90M	-0.13	33,335 shs	2,490 shs

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EVFM Evofem Biosciences	-4.92%	-4.92%	-17.14%	-22.67%	-36.26%
EVLO Evelo Biosciences	0.00%	0.00%	-50.00%	0.00%	-80.00%
REVB Revelation Biosciences	+5.52%	+23.03%	-14.31%	-40.97%	-84.07%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EVFM Evofem Biosciences	0.00	N/A	N/A	N/A
EVLO Evelo Biosciences	0.00	N/A	N/A	N/A
REVB Revelation Biosciences	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest REVB, EVLO, and EVFM Analyst Ratings

Date	Company	Brokerage	Action	Rating
11/10/2026	REVB Revelation Biosciences	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E) ➝ Sell (E+)
10/14/2026	REVB Revelation Biosciences	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (E+) ➝ Sell (E)
9/29/2026	REVB Revelation Biosciences	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E) ➝ Sell (E+)
8/25/2026	REVB Revelation Biosciences	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (E+) ➝ Sell (E)

(Data available from 11/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EVFM Evofem Biosciences	$11.39M	0.07	N/A	N/A	($2.64) per share	0.00
EVLO Evelo Biosciences	N/A	N/A	N/A	N/A	N/A	N/A
REVB Revelation Biosciences	N/A	N/A	N/A	N/A	$10.59 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EVFM Evofem Biosciences	$52.98M	-$0.13	N/A	N/A	N/A	-46.42%	-91.97%	-61.93%	N/A
EVLO Evelo Biosciences	-$114.53M	-$0.66	N/A	N/A	N/A	N/A	N/A	N/A	11/17/2026 (Estimated)
REVB Revelation Biosciences	-$8.91M	-$42.52	N/A	N/A	N/A	N/A	-124.23%	-98.96%	N/A

Latest REVB, EVLO, and EVFM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
11/17/2026	N/A	EVLO Evelo Biosciences	-$10.1333	N/A	N/A	N/A	N/A	N/A
11/5/2026	Q3 2026	REVB Revelation Biosciences	-$6.16	-$5.92	+$0.24	-$5.92	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
EVFM Evofem Biosciences	N/A	N/A	N/A	N/A	N/A
EVLO Evelo Biosciences	N/A	N/A	N/A	N/A	N/A
REVB Revelation Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EVFM Evofem Biosciences	N/A	0.11	0.09
EVLO Evelo Biosciences	N/A	N/A	N/A
REVB Revelation Biosciences	N/A	3.98	6.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EVFM Evofem Biosciences	0.22%
EVLO Evelo Biosciences	0.31%
REVB Revelation Biosciences	12.80%

Insider Ownership

Company	Insider Ownership
EVFM Evofem Biosciences	0.01%
EVLO Evelo Biosciences	1.02%
REVB Revelation Biosciences	4.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EVFM Evofem Biosciences	29	132.53 million	113.12 million	Not Optionable
EVLO Evelo Biosciences	120	18.84 million	18.79 million	No Data
REVB Revelation Biosciences	9	680,000	650,000	Not Optionable

REVB, EVLO, and EVFM Headlines

Recent News About These Companies

Revelation Biosciences, Inc. Announces Financial Results For the Three and Nine Months Ended September 30, 2026

November 5, 2026 | businesswire.com

Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026

October 16, 2026 | finance.yahoo.com

Revelation Biosciences(REVB)股价连创新低，流动性及经营承压

September 28, 2026 | eeo.com.cnE

Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study

August 19, 2026 | finance.yahoo.com

REVB approaching a critical inflection point

August 7, 2026 | msn.com

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026

August 6, 2026 | accessnewswire.comA

Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury

August 3, 2026 | accessnewswire.comA

Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 21, 2026 | accessnewswire.comA

Revelation Biosciences, Inc.: Revelation Biosciences Announces Adoption of Stockholder Rights Plan

July 10, 2026 | finanznachrichten.de

Revelation Biosciences Announces Adoption of Stockholder Rights Plan

July 10, 2026 | accessnewswire.comA

Revelation Biosciences Expands Acute Kidney Injury Advisory Board

June 1, 2026 | accessnewswire.comA

Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders

May 11, 2026 | accessnewswire.comA

REVB Poised for Big Year

May 8, 2026 | finance.yahoo.com

Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026

May 7, 2026 | accessnewswire.comA

Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board

April 6, 2026 | accessnewswire.comA

Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study

March 30, 2026 | oklahoman.comO

Revelation Biosciences (REVB) price target decreased by 37.65% to 54.06

March 28, 2026 | msn.com

REMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference

March 24, 2026 | accessnewswire.comA

Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference

March 19, 2026 | accessnewswire.comA

Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025

February 26, 2026 | accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

REVB, EVLO, and EVFM Company Descriptions

Evofem Biosciences NASDAQ:EVFM

$0.0062 +0.00 (+6.90%)

As of 11:12 AM Eastern

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

Evelo Biosciences NASDAQ:EVLO

Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Revelation Biosciences NASDAQ:REVB

$4.27 -0.11 (-2.51%)

As of 12:02 PM Eastern

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest REVB, EVLO, and EVFM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest REVB, EVLO, and EVFM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

REVB, EVLO, and EVFM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

REVB, EVLO, and EVFM Company Descriptions

Evofem Biosciences NASDAQ:EVFM

Evelo Biosciences NASDAQ:EVLO

Revelation Biosciences NASDAQ:REVB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest REVB, EVLO, and EVFM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest REVB, EVLO, and EVFM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

REVB, EVLO, and EVFM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

REVB, EVLO, and EVFM Company Descriptions

Evofem Biosciences NASDAQ:EVFM

Evelo Biosciences NASDAQ:EVLO

Revelation Biosciences NASDAQ:REVB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools